BioSpace News Archive

Phanes Therapeutics, Inc. announced that it has entered into a clinical collaboration agreement with Merck to study PT886, its first-in-class bispecific antibody targeting claudin 18.2 and CD47, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas.

Abbisko Therapeutics Co., Ltd. announced that the results of the company’s two preclinical studies published at the 35th International Molecular Targets and Cancer Treatment Conference be held in Boston, U.S. These two research results respectively demonstrate the latest preclinical research progress of the next generation of PRMT5*MTA inhibitors and small molecule brain penetrant PD-L1 inhibitors in Abbisko’s pipeline.

Immunic, Inc. announced the presentation of data from the company’s phase 2 CALDOSE-1 trial of vidofludimus calcium in an oral presentation at the United European Gastroenterology Week 2023, taking place October 14-17 in Copenhagen.

SwanBio Therapeutics announced the addition of two industry veterans to the company’s leadership team: John Tsai, MD as executive chair, and Christopher “Topher” Brooke as chief operating officer.

Merck, known as MSD outside of the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a monotherapy for the adjuvant treatment of adults with non-small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

BD announced the most recent results of a recycling pilot to manage discarded syringes and needles that led to 40,000 pounds of medical waste being recycled and diverted from disposal.

NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission on Friday, October 13, 2023.

Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, announced the closing of $4.3 million in a second round of seed financing, bringing the total raised to date to $10.7 million.

Lyra Therapeutics, Inc. announced the appointment of Ronan O’Brien, as Chief Legal Officer, effective October 16, 2023.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, reported preclinical data highlighting the therapeutic potential in liquid and solid tumors of potent and selective heterobifunctional degraders of MDM2, including KT-253.